PubRank

F J van Kemenade

Author PubWeight™ 34.34‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007 5.81
2 Endothelial cell chimerism after renal transplantation and vascular rejection. Lancet 2001 2.35
3 Cutting edge: polycomb gene expression patterns reflect distinct B cell differentiation stages in human germinal centers. J Immunol 2000 1.83
4 Coexpression of BMI-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin's disease. Am J Pathol 2000 1.69
5 HPV DNA testing in population-based cervical screening (VUSA-Screen study): results and implications. Br J Cancer 2012 1.53
6 HPV infection in women with and without cervical cancer in Conakry, Guinea. Br J Cancer 2009 1.50
7 Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands. Br J Cancer 2006 1.43
8 High-risk HPV type-specific clearance rates in cervical screening. Br J Cancer 2007 1.24
9 Distinct BMI-1 and EZH2 expression patterns in thymocytes and mature T cells suggest a role for Polycomb genes in human T cell differentiation. J Immunol 2001 1.20
10 Human papillomavirus infection in women with and without cervical cancer in Karachi, Pakistan. Br J Cancer 2010 1.10
11 HPV testing and monitoring of women after treatment of CIN 3: review of the literature and meta-analysis. Obstet Gynecol Surv 2004 1.10
12 [The 1996 revision of the Dutch cervical cancer screening programme: increased coverage, fewer repeat smears and less opportunistic screening]. Ned Tijdschr Geneeskd 2007 1.09
13 Comparison of GP5+/6+-PCR and SPF10-line blot assays for detection of high-risk human papillomavirus in samples from women with normal cytology results who develop grade 3 cervical intraepithelial neoplasia. J Clin Microbiol 2008 0.96
14 Comparison of Hybrid capture 2 testing at different thresholds with cytology as primary cervical screening test. Br J Cancer 2010 0.88
15 The contribution of HPV18 to cervical cancer is underestimated using high-grade CIN as a measure of screening efficiency. Br J Cancer 2007 0.88
16 Clinical validation of the HPV-risk assay, a novel real-time PCR assay for detection of high-risk human papillomavirus DNA by targeting the E7 region. J Clin Microbiol 2014 0.87
17 Clinical validation of the Abbott RealTime High Risk HPV assay according to the guidelines for human papillomavirus DNA test requirements for cervical screening. J Clin Microbiol 2013 0.87
18 The Aptima HPV assay fulfills the cross-sectional clinical and reproducibility criteria of international guidelines for human papillomavirus test requirements for cervical screening. J Clin Microbiol 2013 0.85
19 Low arginine plasma levels do not aggravate renal blood flow after experimental renal ischaemia/reperfusion. Eur J Vasc Endovasc Surg 2001 0.82
20 Sharing cross-reactive groups of MHC class I improves long-term graft survival. Kidney Int 1999 0.82
21 Methylation marker analysis of self-sampled cervico-vaginal lavage specimens to triage high-risk HPV-positive women for colposcopy. Int J Cancer 2014 0.81
22 Cytology history preceding cervical cancer diagnosis: a regional analysis of 286 cases. Br J Cancer 2011 0.81
23 Long-term CIN3+ risk in women with abnormal cytology; role of hrHPV testing. Br J Cancer 2012 0.81
24 Implementation of human papillomavirus testing in cervical screening without a concomitant decrease in participation rate. J Clin Pathol 2006 0.78
25 High-risk human papillomavirus is present in cytologically false-negative smears: an analysis of "normal" smears preceding CIN2/3. J Clin Pathol 2007 0.78
26 Agreement between colposcopic impression and histological diagnosis among human papillomavirus type 16-positive women: a clinical trial using dynamic spectral imaging colposcopy. BJOG 2012 0.78
27 [A falsely reassuring cervical smear in adenocarcinoma of the external os]. Ned Tijdschr Geneeskd 2008 0.75
28 [Sarcoidosis: immunopathogenesis and the potential of immunotherapy]. Ned Tijdschr Geneeskd 2003 0.75
29 HLA class I and II molecules present influenza virus antigens with different kinetics. Eur J Immunol 1992 0.75